晚期肾癌-话题@MedSci

#晚期肾癌#

35篇内容 | 2097人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1367015, encodeId=9123136e0151b, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, objectType=article, longId=160546, objectId=fa9316054665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9316054665, replyNumber=0, likeNumber=72, createdTime=2019-02-21, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9316054665, moduleTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9316054665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367014, encodeId=4566136e01417, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=Opdivo/Yervoy联合免疫疗法获批成为晚期肾癌的一线治疗药物, objectType=article, longId=135804, objectId=accc1358048f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=accc1358048f, replyNumber=0, likeNumber=66, createdTime=2018-04-20, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=accc1358048f, moduleTitle=Opdivo/Yervoy联合免疫疗法获批成为晚期肾癌的一线治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=accc1358048f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367013, encodeId=5dfe136e0133b, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=医保+慈援，解晚期肾癌患者后顾之忧, objectType=article, longId=134861, objectId=53801348612f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53801348612f, replyNumber=0, likeNumber=68, createdTime=2018-04-12, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53801348612f, moduleTitle=医保+慈援，解晚期肾癌患者后顾之忧, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53801348612f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367012, encodeId=9279136e012ef, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=NEJM：纳武单抗+伊匹单抗治疗晚期肾癌效果优于舒尼替尼, objectType=article, longId=133126, objectId=6d2313312635, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d2313312635, replyNumber=0, likeNumber=172, createdTime=2018-03-24, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d2313312635, moduleTitle=NEJM：纳武单抗+伊匹单抗治疗晚期肾癌效果优于舒尼替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d2313312635)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367011, encodeId=b0c2136e01151, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=ASCO-GU 2018 | 肾癌辅助治疗与晚期肾癌治疗进展, objectType=article, longId=130005, objectId=990b13000574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=990b13000574, replyNumber=0, likeNumber=100, createdTime=2018-02-16, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=990b13000574, moduleTitle=ASCO-GU 2018 | 肾癌辅助治疗与晚期肾癌治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=990b13000574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367010, encodeId=34c4136e01033, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=ASCO-GU 2018| 从IMmotion151研究看晚期肾癌未来一线治疗, objectType=article, longId=129844, objectId=e68312984417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e68312984417, replyNumber=0, likeNumber=72, createdTime=2018-02-14, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e68312984417, moduleTitle=ASCO-GU 2018| 从IMmotion151研究看晚期肾癌未来一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e68312984417)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367009, encodeId=c5a9136e009ec, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=J Clin Oncol：晚期肾癌新药卡博替尼：能否兼顾生命的长度和质量？, objectType=article, longId=128872, objectId=10101288e283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10101288e283, replyNumber=0, likeNumber=75, createdTime=2018-02-06, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10101288e283, moduleTitle=J Clin Oncol：晚期肾癌新药卡博替尼：能否兼顾生命的长度和质量？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10101288e283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367008, encodeId=8ca2136e00863, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=卡博替尼获批用于晚期肾癌一线治疗, objectType=article, longId=124201, objectId=cfd212420167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfd212420167, replyNumber=0, likeNumber=90, createdTime=2017-12-23, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfd212420167, moduleTitle=卡博替尼获批用于晚期肾癌一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfd212420167)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367007, encodeId=891f136e007e4, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=Lancet Oncol：晚期肾癌VEGF靶向治疗进展后， cabozantinib成新标准？, objectType=article, longId=108931, objectId=e67710893136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e67710893136, replyNumber=0, likeNumber=71, createdTime=2017-08-17, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e67710893136, moduleTitle=Lancet Oncol：晚期肾癌VEGF靶向治疗进展后， cabozantinib成新标准？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e67710893136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367006, encodeId=4d22136e006e2, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=J CLIN ONCOL:针对晚期肾癌的靶向药物表现出治疗新希望！, objectType=article, longId=103518, objectId=c040103518c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c040103518c8, replyNumber=0, likeNumber=74, createdTime=2017-06-28, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c040103518c8, moduleTitle=J CLIN ONCOL:针对晚期肾癌的靶向药物表现出治疗新希望！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c040103518c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367005, encodeId=5b57136e0056e, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=舒尼替尼对晚期肾癌患者免疫功能的影响, objectType=article, longId=84918, objectId=c3178491894, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3178491894, replyNumber=0, likeNumber=71, createdTime=2016-12-22, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3178491894, moduleTitle=舒尼替尼对晚期肾癌患者免疫功能的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3178491894)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367004, encodeId=b33b136e00448, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=CSCO 2016：中国晚期肾癌靶向治疗的思考, objectType=article, longId=78386, objectId=38a4e8386f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38a4e8386f4, replyNumber=0, likeNumber=39, createdTime=2016-09-26, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38a4e8386f4, moduleTitle=CSCO 2016：中国晚期肾癌靶向治疗的思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38a4e8386f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367003, encodeId=6c34136e003d3, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=FDA批准Lenvatinib+依维莫司联合治疗晚期肾癌, objectType=article, longId=68497, objectId=52236849e07, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52236849e07, replyNumber=0, likeNumber=69, createdTime=2016-05-19, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52236849e07, moduleTitle=FDA批准Lenvatinib+依维莫司联合治疗晚期肾癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52236849e07)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367002, encodeId=18e1136e002ae, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=NEJM：卡博替尼治疗晚期肾癌效果更佳, objectType=article, longId=58383, objectId=9ab8583833c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ab8583833c, replyNumber=0, likeNumber=73, createdTime=2015-11-07, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ab8583833c, moduleTitle=NEJM：卡博替尼治疗晚期肾癌效果更佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ab8583833c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367001, encodeId=8159136e001fe, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=CSMO 2014 ：晚期肾癌分子靶向治疗研究进展, objectType=article, longId=37819, objectId=c61b3e819a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c61b3e819a7, replyNumber=0, likeNumber=84, createdTime=2014-07-17, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c61b3e819a7, moduleTitle=CSMO 2014 ：晚期肾癌分子靶向治疗研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c61b3e819a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367000, encodeId=a816136e0007b, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=FDA：阿昔替尼（Inlyta）治疗晚期肾癌获准, objectType=article, longId=3816, objectId=874b381675, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=874b381675, replyNumber=0, likeNumber=75, createdTime=2012-02-05, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=874b381675, moduleTitle=FDA：阿昔替尼（Inlyta）治疗晚期肾癌获准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=874b381675)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期肾癌

2020-05-29

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率

2019-02-21

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

Opdivo/Yervoy联合免疫疗法获批成为晚期肾癌的一线治疗药物

2018-04-20

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

医保+慈援，解晚期肾癌患者后顾之忧

2018-04-12

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

NEJM：纳武单抗+伊匹单抗治疗晚期肾癌效果优于舒尼替尼

2018-03-24

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

ASCO-GU 2018 | 肾癌辅助治疗与晚期肾癌治疗进展

2018-02-16

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

ASCO-GU 2018| 从IMmotion151研究看晚期肾癌未来一线治疗

2018-02-14

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

J Clin Oncol：晚期肾癌新药卡博替尼：能否兼顾生命的长度和质量？

2018-02-06

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

卡博替尼获批用于晚期肾癌一线治疗

2017-12-23

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

Lancet Oncol：晚期肾癌VEGF靶向治疗进展后， cabozantinib成新标准？

2017-08-17

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

J CLIN ONCOL:针对晚期肾癌的靶向药物表现出治疗新希望！

2017-06-28

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

舒尼替尼对晚期肾癌患者免疫功能的影响

2016-12-22

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

CSCO 2016：中国晚期肾癌靶向治疗的思考

2016-09-26

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

FDA批准Lenvatinib+依维莫司联合治疗晚期肾癌

2016-05-19

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

NEJM：卡博替尼治疗晚期肾癌效果更佳

2015-11-07

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

CSMO 2014 ：晚期肾癌分子靶向治疗研究进展

2014-07-17

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

FDA：阿昔替尼（Inlyta）治疗晚期肾癌获准

2012-02-05

科室
- - 订阅+
  - 更多科室
工具
服务